From the Editor’s desk.…
EASL LiverTree™, Richard Moreau, 256726
JHEP at a glance (December 2018)
EASL LiverTree™, Journal of Hepatology, 256727
In Memoriam: Professor Bernard Portmann 1940–2018
EASL LiverTree™, Roger S. Williams, 256728
In Memoriam: Jan De Groote (1925–2018)
EASL LiverTree™, Frederik Nevens, 256729
MACHT – Outpatient albumin infusions do not prevent complications of cirrhosis in patients on the liver transplant waiting list
EASL LiverTree™, Alastair O'Brien, 256730
Need for surveillance of hepatocellular carcinoma in patients with alcoholic cirrhosis
EASL LiverTree™, Ramon Bataller, 256731
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients
EASL LiverTree™, Hadas Dvory-Sobol, 256732
Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels
EASL LiverTree™, Ulrike Protzer, 256733
Pregnancy in idiopathic non-cirrhotic portal hypertension: A multicentric study on maternal and fetal management and outcome
EASL LiverTree™, Pierre-Emmanuel Rautou, 256734
Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial
EASL LiverTree™, Pere Ginés, 256735
Supportive and palliative care in people with cirrhosis: International systematic review of the perspective of patients, family members and health professionals
EASL LiverTree™, Joseph T.S. Low, 256736
Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis
EASL LiverTree™, Nathalie Ganne-Carrié, 256737
Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection
EASL LiverTree™, Philip JOHNSON, 256738
Immune and metabolic shifts during neonatal development reprogram liver identity and function
EASL LiverTree™, Gustavo Batista Menezes, 256739
Claudin-3 regulates bile canalicular paracellular barrier and cholesterol gallstone core formation in mice
EASL LiverTree™, Sachiko Tsukita, 256740
The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine
EASL LiverTree™, Robert Fontana, 256741
Inactivation of caspase 8 in liver parenchymal cells confers protection against murine obstructive cholestasis
EASL LiverTree™, Christian Trautwein, 256742
miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis
EASL LiverTree™, Manuel Romero Gomez, 256743
Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease
EASL LiverTree™, Henry Chan, 256744
Clinical and histologic features of adults with alpha-1 antitrypsin deficiency in a non-cirrhotic cohort
EASL LiverTree™, Virginia Clark, 256745
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options
EASL LiverTree™, Zobair Younossi, 256746
Primary biliary cholangitis: A tale of epigenetically-induced secretory failure?
EASL LiverTree™, Jesus Banales, 256747
Acute-on-chronic liver failure vs. traditional acute decompensation of cirrhosis
EASL LiverTree™, Thierry Gustot, 256748
Hepatic progenitors in liver regeneration
EASL LiverTree™, Stuart J Forbes, 256749
Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study
EASL LiverTree™, Vincent Mallet, 256750
Reply to: “Incidence of grade 3–4 liver injury under immune checkpoints inhibitors: A retrospective study”
EASL LiverTree™, Didier Samuel, 256751
Finding fibroblast growth factor 19 during cholestasis: Does x mark the spot?
EASL LiverTree™, Rowan van Golen, 256752
Reply to: “Finding fibroblast growth factor 19 during cholestasis: Does x mark the spot?
EASL LiverTree™, Bernd Schnabl, 256753
Expression of Concern
EASL LiverTree™, Journal of Hepatology, 256754
From the Editor’s desk.…
EASL LiverTree™, Richard Moreau, 256757
JHEP at a glance (December 2018)
EASL LiverTree™, Journal of Hepatology, 256758
In Memoriam: Professor Bernard Portmann 1940–2018
EASL LiverTree™, Roger S. Williams, 256759
In Memoriam: Jan De Groote (1925–2018)
EASL LiverTree™, Frederik Nevens, 256760
MACHT – Outpatient albumin infusions do not prevent complications of cirrhosis in patients on the liver transplant waiting list
EASL LiverTree™, Alastair O'Brien, 256761
Need for surveillance of hepatocellular carcinoma in patients with alcoholic cirrhosis
EASL LiverTree™, Ramon Bataller, 256762
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients
EASL LiverTree™, Hadas Dvory-Sobol, 256763
Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels
EASL LiverTree™, Ulrike Protzer, 256764
Pregnancy in idiopathic non-cirrhotic portal hypertension: A multicentric study on maternal and fetal management and outcome
EASL LiverTree™, Pierre-Emmanuel Rautou, 256765
Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial
EASL LiverTree™, Pere Ginés, 256766
Supportive and palliative care in people with cirrhosis: International systematic review of the perspective of patients, family members and health professionals
EASL LiverTree™, Joseph T.S. Low, 256767
Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis
EASL LiverTree™, Nathalie Ganne-Carrié, 256768
Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection
EASL LiverTree™, Philip JOHNSON, 256769
Immune and metabolic shifts during neonatal development reprogram liver identity and function
EASL LiverTree™, Gustavo Batista Menezes, 256770
Claudin-3 regulates bile canalicular paracellular barrier and cholesterol gallstone core formation in mice
EASL LiverTree™, Sachiko Tsukita, 256771
The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine
EASL LiverTree™, Robert Fontana, 256772
Inactivation of caspase 8 in liver parenchymal cells confers protection against murine obstructive cholestasis
EASL LiverTree™, Christian Trautwein, 256773
miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis
EASL LiverTree™, Manuel Romero Gomez, 256774
Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease
EASL LiverTree™, Henry Chan, 256775
Clinical and histologic features of adults with alpha-1 antitrypsin deficiency in a non-cirrhotic cohort
EASL LiverTree™, Virginia Clark, 256776
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options
EASL LiverTree™, Zobair Younossi, 256777
Primary biliary cholangitis: A tale of epigenetically-induced secretory failure?
EASL LiverTree™, Jesus Banales, 256778
Acute-on-chronic liver failure vs. traditional acute decompensation of cirrhosis
EASL LiverTree™, Thierry Gustot, 256779
Hepatic progenitors in liver regeneration
EASL LiverTree™, Stuart J Forbes, 256780
Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study
EASL LiverTree™, Vincent Mallet, 256781
Reply to: “Incidence of grade 3–4 liver injury under immune checkpoints inhibitors: A retrospective study”
EASL LiverTree™, Didier Samuel, 256782
Finding fibroblast growth factor 19 during cholestasis: Does x mark the spot?
EASL LiverTree™, Rowan van Golen, 256783
Reply to: “Finding fibroblast growth factor 19 during cholestasis: Does x mark the spot?
EASL LiverTree™, Bernd Schnabl, 256784
Expression of Concern
EASL LiverTree™, Journal of Hepatology, 256785
From the Editor’s desk....
EASL LiverTree™, Richard Moreau, 234529
JHEP at a glance (November 2018)
EASL LiverTree™, Journal of Hepatology, 234530
Multi-organ quantitative MRI for the assessment of liver disease – A whole much more than the sum of its parts
EASL LiverTree™, Manil D. Chouhan, 234531
Interspecies chimeric livers: A step closer to solving the problem of transplantable organ shortage?
EASL LiverTree™, Burcin Ekser, 234532
Ex vivo liver resection and autotransplantation: An emerging option in selected indications
EASL LiverTree™, Tomoaki Kato, 234533
Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer
EASL LiverTree™, ATK Member, 234540
Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy
EASL LiverTree™, DAEHEE CHOI, 234541
Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia
EASL LiverTree™, Fabienne RAJAS, 234542
Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C
EASL LiverTree™, George Ioannou, 234543
The nuclear bile acid receptor FXR is a PKA- and FOXA2-sensitive activator of fasting hepatic gluconeogenesis
EASL LiverTree™, Philippe LEFEBVRE, 234544
Caspase recruitment domain 6 protects against hepatic ischemia/reperfusion injury by suppressing ASK1
EASL LiverTree™, Hongliang Li, 234545
Identification of a xenobiotic as a potential environmental trigger in primary biliary cholangitis
EASL LiverTree™, Matthew C. Wright, 234546
Regulation of epithelial injury and bile duct obstruction by NLRP3, IL-1R1 in experimental biliary atresia
EASL LiverTree™, Jorge Bezerra, 234547
Abnormal neutrophil traps and impaired efferocytosis contribute to liver injury and sepsis severity after binge alcohol use
EASL LiverTree™, Gyongyi Szabo, 234548
An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers
EASL LiverTree™, Giulio Marchesini, 234549
Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease
EASL LiverTree™, Ian A. Rowe, 234556
Reply to: “Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease”
EASL LiverTree™, Salvatore Petta, 234557
Antiviral therapy in hepatitis B virus-infected immunotolerant children, exploring a new land
EASL LiverTree™, Mohamed Aly Mokhles, 234558
Reply to: “Antiviral therapy in hepatitis B virus-infected immunotolerant children, exploring a new land”
EASL LiverTree™, Pan Zhao, 234559
Corrigendum to “EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis” [J Hepatol 69 (2018) 406–460]
EASL LiverTree™, Journal of Hepatology, 234560
Corrigendum to “Alveolar echinococcosis: From a deadly disease to a well-controlled infection. Relative survival and economic analysis in Switzerland over the last 35 years” [J Hepatol 49 (2008) 72–77]
EASL LiverTree™, Beat Muellhaupt, 234561
From the Editor’s desk....
EASL LiverTree™, Richard Moreau, 256693
JHEP at a glance (November 2018)
EASL LiverTree™, Journal of Hepatology, 256694
Multi-organ quantitative MRI for the assessment of liver disease – A whole much more than the sum of its parts
EASL LiverTree™, Manil D. Chouhan, 256695
Interspecies chimeric livers: A step closer to solving the problem of transplantable organ shortage?
EASL LiverTree™, Burcin Ekser, 256696
Liver transplantation in patients with multiple organ failures: Feasibility and outcomes
EASL LiverTree™, Paul Joseph Thuluvath, 256703
Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer
EASL LiverTree™, ATK Member, 256704
Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy
EASL LiverTree™, DAEHEE CHOI, 256705
Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia
EASL LiverTree™, Fabienne RAJAS, 256706
Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C
EASL LiverTree™, George Ioannou, 256707
The nuclear bile acid receptor FXR is a PKA- and FOXA2-sensitive activator of fasting hepatic gluconeogenesis
EASL LiverTree™, Philippe LEFEBVRE, 256708
Caspase recruitment domain 6 protects against hepatic ischemia/reperfusion injury by suppressing ASK1
EASL LiverTree™, Hongliang Li, 256709
Identification of a xenobiotic as a potential environmental trigger in primary biliary cholangitis
EASL LiverTree™, Matthew C. Wright, 256710
Regulation of epithelial injury and bile duct obstruction by NLRP3, IL-1R1 in experimental biliary atresia
EASL LiverTree™, Jorge Bezerra, 256711
Abnormal neutrophil traps and impaired efferocytosis contribute to liver injury and sepsis severity after binge alcohol use
EASL LiverTree™, Gyongyi Szabo, 256712
Reply to: “Prevalent acute-on-chronic liver failure and response to corticosteroids in alcoholic hepatitis”
EASL LiverTree™, Thomas Sersté, 256719
Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease
EASL LiverTree™, Ian A. Rowe, 256720
Reply to: “Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease”
EASL LiverTree™, Salvatore Petta, 256721
Antiviral therapy in hepatitis B virus-infected immunotolerant children, exploring a new land
EASL LiverTree™, Mohamed Aly Mokhles, 256722
Reply to: “Antiviral therapy in hepatitis B virus-infected immunotolerant children, exploring a new land”
EASL LiverTree™, Pan Zhao, 256723
Corrigendum to “EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis” [J Hepatol 69 (2018) 406–460]
EASL LiverTree™, Journal of Hepatology, 256724
Corrigendum to “Alveolar echinococcosis: From a deadly disease to a well-controlled infection. Relative survival and economic analysis in Switzerland over the last 35 years” [J Hepatol 49 (2008) 72–77]
EASL LiverTree™, Beat Muellhaupt, 256725

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings